Up-regulation of urokinase-type plasminogen activator by insulin-like growth factor-I depends upon phosphatidylinositol-3 kinase and mitogen-activated protein kinase kinase

Cancer Research

Volumn 61, Issue 4, 2001, Pages 1367-1374

  Dunn, Sandra E ^a   Torres, Johann V ^b   Oh, Jennifer S ^a   Cykert, David M ^a   Barrett, J Carl ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 2 MORPHOLINO 8 PHENYLCHROMONE; HERBIMYCIN A; LUCIFERASE; MITOGEN ACTIVATED PROTEIN KINASE KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; RAPAMYCIN; S6 KINASE; SOMATOMEDIN C; UROKINASE;

ARTICLE; BINDING SITE; BREAST CANCER; BREAST CARCINOGENESIS; CANCER RECURRENCE; CANCER SURVIVAL; CONTROLLED STUDY; DIAGNOSTIC VALUE; DRUG TARGETING; GENE EXPRESSION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROGNOSIS; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION; TUMOR CELL LINE;

1-PHOSPHATIDYLINOSITOL 3-KINASE; BENZOQUINONES; BREAST NEOPLASMS; CELL MOVEMENT; CHROMONES; ENZYME INHIBITORS; FLAVONOIDS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INSULIN-LIKE GROWTH FACTOR I; LACTAMS, MACROCYCLIC; MAP KINASE SIGNALING SYSTEM; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; MORPHOLINES; PROMOTER REGIONS (GENETICS); QUINONES; RECEPTOR, IGF TYPE 1; RECEPTORS, ESTROGEN; RNA, MESSENGER; STIMULATION, CHEMICAL; TRANSCRIPTION FACTOR AP-1; TUMOR CELLS, CULTURED; UP-REGULATION; URINARY PLASMINOGEN ACTIVATOR;

EID: 0035866381     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (53)

1. Urokinase-type plasminogen activator antigen and early relapse in breast cancer
2. Prognostic value of uPA and p53 accumulation measured by quantitative biochemical assays in 1245 primary breast cancer patients: A multicenter study
3. The urokinase plasminogen activator system as a target for prognostic studies in breast cancer
4. Clinical impact of the plasminogen activation system in tumor invasion and metastasis: Prognostic relevance and target for therapy
5. Elevation of serum level of vascular endothelial growth factor as a new predictor of recurrence and disease progression in patients with superficial urothelial cancer
6. In vitro degradation of radiolabelled, intact basement membrane mediated by cellular plasminogen activator
7. Urokinase-type plasminogen activation in three human breast cancer cell lines correlates with their in vitro invasiveness
8. Plasminogen activators, tissue degradation, and cancer
9. Regulation of matrix metalloproteinases
10. Tumor-associated urokinase-type plasminogen activator: Biological and clinical significance
11. Reduced metastasis of polyoma virus middle T antigen-induced mammary cancer in plasminogen-deficient mice
12. Urokinase overproduction results in increased skeletal metastasis by prostate cancer cell in vivo
13. Antimetastetic effect of amiloride in an animal tumor model
14. Prevention of breast cancer growth, invasion, and metastasis by antiestrogen Tamoxifen alone or in combination with urokinase inhibitor B-428
15. A peptide derived from the nonreceptor binding region of urokinase plasminogen activator (uPA) inhibits tumor progression and angiogenesis and induces tumor cell death in vivo
16. Breast cancer: Prognostic significance of c-erb-B2 and int-2 amplification compared with DNA ploidy, S-phase fraction, and conventional clinicopathological features
17. Insulin-like growth factor-I receptor overexpression mediates cellular radioresistance and local breast cancer recurrence after lumpectomy and radiation
18. The ETS-1 and ETS-2 transcription factors activate the promoters for invasion-associated urokinase and collagenase genes in response to epidermal growth factor
19. Up-regulation of urokinase-type activator expression by the HER2/neu proto-oncogene
20. The insulin-like growth factor-I elevates urokinase-type plasminogen activator-1 in human breast cancer cells: A new avenue for breast cancer therapy
21. Persistent activation of mitogen-activated protein kinases p42 and p44 and ets-2 phosphorylation in response to colony-stimulated factor I/c-fms signaling
22. Regulation of breast cancer growth by insulin-like growth factors
23. Insulin-like growth factor-I alters drug sensitivity of human breast cancer cells by inhibition of apoptosis induced by diverse anticancer drugs
24. A dominant negative mutant of the insulin-like growth factor-1 receptor inhibits the adhesion, invasion, and metastasis of breast cancer
25. The roles of integrins and extracellular matrix proteins in the insulin-like growth factor-1 stimulated chemotaxis of human breast cancer cells
26. Interference of the IGF system as a strategy to inhibit breast cancer growth
27. Herbimycin A induces the 20 S proteasome and ubiquitin dependent degradation of receptor tyrosine kinases
28. Hyperexpression of mitogen-activated protein kinase in human breast cancer
29. Estrogen receptor, growth factor receptor, and protooncogene protein activities and possible signal transduction crosstalk in estrogen-dependent and -independent breast cancer cell lines
30. Role of AKTI in 17 b-estradiol and insulin-like growth factor I (IGF-1) dependent proliferation and prevention of apoptosis in MCF-7 breast carcinoma cells
31. Activation and inhibition of the AP-1 complex in human breast cancer cells
32. The influence of antiestrogens on the release of plasminogen activator (uPA) by MDA-MB-231 and MCF-7 breast cancer cells
33. Overexpression of a p-glycoprotein in hepatocellular carcinomas from woodchuck hepatitis virus-infected woodchucks (Marmota monax)
34. Circulating insulin-like growth factor-1 and the risk of breast cancer
35. Insulin-like growth factor-1 triggered cell migration and invasion are mediated by matrix metalloproteinase-9
36. Matrix metalloproteinases degrade insulin-like growth factor-binding protein-3 in dermal fibroblast cultures
37. Identification of insulin-like growth factor-binding protein-1 as a potential physiological substrate for human stromelysin-3
38. Autocrine regulation of cell proliferation by the insulin-like growth factor-1 (IGF) and IGF binding protein-3 protease system in a human prostate carcinoma cell line (PC-3)
39. Mitogenic signaling of insulin-like growth factor-1 in MCF-7 human breast cancer cells requires phosphatidylinositol 3-kinase and is independent of mitogen-activated protein kinase
40. Novel functional PI 3-kinase antagonist inhibit cell growth and tumorigenicity in human breast cancer cell lines
41. The benzoquinone ansamycin 17-allylamino-17-demethoxygeldanamycin binds to HSP90 and shares important biological activities with geldanamycin
42. Depletion of erb-B2 gene product p185 by benzoquinoid ansamycins
43. Depletion of p185, Ref-1, and mutant p53 by geldanamycin derivatives correlates with antiproliferative activity
44. Expression is controlled post-translationally via a phosphatidylinositnl 3-kinase/AKT dependent pathway
45. Destabilization of Raf-1 by geldanamycin leads to disruption of Ref-1-MEK-mitogen activated protein kinase signaling pathway
46. Effects of geldanamycin on signaling through activator-protein I in hypoxic HT29 human colon adenocarcinoma cells
47. The geldanamycins are potent inhibitors of the hepatocyte growth factor/scatter factor-Met-urokinase plasminogen activator-plasmin proteolytic network
48. DT-Diaphorase expression and tumor cell sensitivity to 17-allylamino-17-demethoxygeldanamycin, an inhibitor of heat shock protein 90
49. The role of jun, fos, and the AP-1 complex in cell proliferation and transformation
50. v-Src activates the expression of 92-kDA type IV collagenase gene through the AP-1 site and the GT box homologous to retinoblastoma control elements
51. The collagenase gene promoter contains a TPA and oncogene-responsive unit encompassing the PEA3 and AP-1 binding sites
52. Erb-B2 overexpression confers PI 3′kinase-dependent invasion capacity on human mammary epithelial cells
53. Transcription factor PEA3 participates in the induction of urokinase plasminogen activator transcription in murine keratinocytes stimulated with epidermal growth factor or phorbol-ester